Compare MGM Resorts International (MGM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs TransMedics Group Inc — how do they compare? MGM Resorts International trades at $29.4 (market cap $7.55B), while TransMedics Group Inc trades at $78.32 (market cap $2.74B). The key difference: MGM Resorts International is far larger — about 2.8× TransMedics Group Inc's market cap, and MGM Resorts International pays a 0.03% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and TransMedics Group Inc for 24 Days on average.
| MGM | TMDX | |
|---|---|---|
Market Cap | $7.55B | $2.74B |
Volume | 5,342,346 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $150.42 |
52-Week Low | $30.00 | $61.99 |
Typical Hold Time | 91 Days | 24 Days |
Enterprise Value | $34.85B | $3.13B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $29.77, down 0.77% for the day amid a bearish technical signal and recent deal uncertainty. The stock has faced pressure after Barry Diller's People Inc. withdrew its $48.30 per share acquisition proposal in September 2026, contributing to a 17% decline year-to-date. Fundamentally, revenue grew to $17.54 billion in 2025, but net income margin compressed to 2.4%, while valuation metrics like a P/E of 18.19 and P/S of 0.45 suggest moderate pricing relative to sales. Analyst consensus remains bullish with a $48.75 price target, but technical indicators show selling pressure with key support at $29.
The outlook for MGM hinges on earnings execution and strategic moves, with Q3 2026 results due October 28 offering a near-term catalyst. Risks include volatile cash flows, high debt levels, and integration challenges from potential M&A. The stock's current discount to analyst targets presents opportunity if operational improvements materialize, but investors face headwinds from competitive pressures and macroeconomic sensitivity.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
